Related Experiment Video
Updated: May 20, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
A Saudi Heart Association Position Statement on the use of DOACs in Patients With Arterial and Venous Thrombosis
Waleed Alhabeeb1, Adel Tash2, Ahmed Aljedai3,4
1Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
Insights
Direct oral anticoagulants (DOACs) offer effective and convenient alternatives to traditional anticoagulants for managing thromboembolic risks in cardiovascular disease. This guidance emphasizes individualized patient assessment for optimal DOAC use and outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Management
Background:
- Direct oral anticoagulants (DOACs) are established as effective alternatives to traditional anticoagulants for managing thromboembolic risks in cardiovascular conditions.
- The Saudi Heart Association (SHA) developed this position statement to guide DOAC use in Saudi Arabia's cardiovascular patient population.
Purpose of the Study:
- To provide expert recommendations on the use of direct oral anticoagulants (DOACs) for patients with cardiovascular disease.
- To address the initiation, maintenance, interruption, and re-initiation of DOAC therapy within the Saudi Arabian healthcare context.
Main Methods:
- A multidisciplinary panel of experts reviewed current evidence and international guidelines on DOACs.
- Consideration was given to the specific healthcare landscape and patient populations in Saudi Arabia.
Main Results:
- DOACs demonstrate comparable or superior efficacy to traditional anticoagulants with a potentially lower bleeding risk and no need for routine monitoring.
- Regular assessment of stroke risk (CHA2DS2-VASc) and bleeding risk (HAS-BLED) is crucial, especially with changing clinical conditions.
- Specific guidance is provided for dosing adjustments in renal/hepatic impairment and for special populations, including those undergoing surgery or with malignancies.
Conclusions:
- DOACs are a valuable therapeutic option due to their efficacy, safety, and convenience.
- Individualized patient assessment, considering stroke risk, bleeding risk, and comorbidities, is essential for optimal DOAC therapy.
- Adherence to SHA recommendations will improve patient care and outcomes in Saudi Arabia.
Background:
Direct oral anticoagulants (DOACs) have emerged as non-inferior and effective alternatives to traditional anticoagulants in managing thromboembolic risks associated with various cardiovascular conditions. This position statement by the Saudi Heart Association (SHA) aims to provide guidance on the use of DOACs in the context of cardiovascular disease, particularly patients with arterial and venous thrombosis.
Methods:
A multidisciplinary panel of experts reviewed current evidence and international guidelines on DOACs, considering the local healthcare context in Saudi Arabia. The statement addresses the initiation, maintenance, interruption, and re-initiation of DOAC therapy across different patient populations.
Results:
DOACs are effective alternatives to traditional anticoagulants with a comparable or lower risk of bleeding and no requirement for frequent monitoring, making them more convenient for patients. It is important to regularly assess stroke risk (CHA2DS2-VASc score) and bleeding risk (HAS-BLED score) before initiating DOAC therapy and during the course of treatment, particularly in patients with changing clinical conditions. Specific factors warrant careful consideration for the use of DOACs in special patient populations. Recommendations are therefore provided for dosing adjustments in renal and hepatic impairment, alongside considerations for patients in different clinical scenarios such as those undergoing surgery or with malignancies.
Conclusion:
DOACs represent a valuable option for clinicians owing to their efficacy, safety and convenience compared to traditional anticoagulants. DOACs should be used based on individualized patient assessment, particularly regarding bleeding risk, stroke risk, and other comorbidities and clinical factors that may affect clinical outcomes. Adherence to the recommendations and guidance provided in this SHA statement is needed to enhance patient care and outcomes in Saudi Arabia.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...